Industry | 2009.09.09
New Teva Data Highlights Advances in MS Treatment Research
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany, September 9-12, 2009. Featured presentations and abstracts will include new data on COPAXONE®, the global leading treatment for
For more information, please visit
http://www.businesswire.com/news/home/20090908005969/en
